GLI1 and neoplasm: This approach is clearly preferable to simply comparing the mean or median GLI1 expression in post-treatment tumor samples in Sonidegib-treated patients versus controls, which would not account for dynamic changes in the biomarkers of interest induced by Sonidegib treatment.